Pharmacokinetics of antiretroviral drug varies with formulation in the target population of children with HIV-1.
about
Young HIV-infected children and their adult caregivers prefer tablets to syrup antiretroviral medications in AfricaRoutine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial.Formulations for children: problems and solutionsSingle-dose nevirapine exposure does not affect response to antiretroviral therapy in HIV-infected African children aged below 3 years.Population pharmacokinetics study of recommended zidovudine doses in HIV-1-infected childrenPharmacokinetics of zidovudine dosed twice daily according to World Health Organization weight bands in Ugandan HIV-infected children.Covariate effects and population pharmacokinetics of lamivudine in HIV-infected children.The role of formulation on the pharmacokinetics of antiretroviral drugs.Dose evaluation of lamivudine in human immunodeficiency virus-infected children aged 5 months to 18 years based on a population pharmacokinetic analysis.A model-based approach for the evaluation of once daily dosing of lamivudine in HIV-infected children.Pharmacokinetics of darunavir after administration of an oral suspension with low-dose ritonavir and with or without food.Effect of Sorbitol on the Pharmacokinetic Profile of Lamivudine Oral Solution in Adults: An Open-Label, Randomized Study.Twenty-Five Years of Lamivudine: Current and Future Use for the Treatment of HIV-1 Infection.
P2860
Q28483158-BAE78519-78C6-4A96-8FF2-FD0406A86885Q30539434-B45F63F1-4A5E-46D3-9C26-4ECE7B4B6BB0Q35135943-E88FA07A-22A2-42E2-B067-E31F432269B3Q36802222-F148693B-66C2-407A-B3DF-9BB1EF0B834EQ37263890-FF278471-AF99-47A7-9ACC-6D89AD0F6054Q37708677-87F5D615-E519-4800-9268-A579FCA56B35Q37731863-281B01EB-0BDE-4037-9B27-9709CA3E1154Q38216047-C26502C4-69E2-4FA7-A897-E8ABC2F4F170Q38771392-78BA0BF2-8D6D-4422-B715-7098064B8929Q39051618-884D5784-709D-4948-92B5-0F809300441AQ42199714-71DD4646-CD46-417E-BC31-252661CDEF6BQ49908214-9B8C7C20-D710-43C1-AA9C-B6533A81F0C5Q52374199-09079A1D-A468-4DC8-9C1A-2A873E838EB4
P2860
Pharmacokinetics of antiretroviral drug varies with formulation in the target population of children with HIV-1.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Pharmacokinetics of antiretrov ...... lation of children with HIV-1.
@en
type
label
Pharmacokinetics of antiretrov ...... lation of children with HIV-1.
@en
prefLabel
Pharmacokinetics of antiretrov ...... lation of children with HIV-1.
@en
P2093
P2860
P356
P1476
Pharmacokinetics of antiretrov ...... lation of children with HIV-1.
@en
P2093
A Kekitiinwa
A S Walker
ARROW Trial Team
C Tumusiime
D M Burger
K K Adkison
M Ssenyonga
P Nahirya-Ntege
P2860
P304
P356
10.1038/CLPT.2011.225
P407
P577
2011-12-21T00:00:00Z